The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMajedie Inv. Regulatory News (MAJE)

Share Price Information for Majedie Inv. (MAJE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 246.00
Bid: 240.00
Ask: 246.00
Change: 1.00 (0.41%)
Spread: 6.00 (2.50%)
Open: 242.00
High: 246.00
Low: 240.00
Prev. Close: 245.00
MAJE Live PriceLast checked at -
Majedie is an Investment Trust

To maximise total shareholder return whilst increasing dividends by more than the rate of inflation over the long-term by investing in securities of publicly quoted companies worldwide, though it may invest in unquoted securities.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results analysis from Kepler Trust Intelligence

2 Jan 2024 15:50

RNS Number : 4166Y
Majedie Investments PLC
02 January 2024
 

Majedie Investments (MAJE)

02/01/2024

Results analysis from Kepler Trust Intelligence

Majedie Investments (MAJE) has released its annual results for the year ending 30/09/2023, the first following the transfer of portfolio management responsibilities to Marylebone Partners in January 2023. Over the period, MAJE's NAV total return increased by 14.1%. The managers report that investment performance between February 2023 (when they assumed investment management responsibility) and the financial year-end was effectively flat.

Over the course of the financial year, MAJE generated a share price total return of 26.2%, which is reflected in the discount narrowing from 25.8% to 18.7%. Subsequently, MAJE's discount has narrowed to 12.1%, as at 29/12/2023.

The dividend policy has changed following the introduction of the new investment policy which will see equal quarterly dividends paid, equating to approximately 3% of NAV over the year - the board hopes this will ensure greater clarity for shareholders.

Chairman Cristopher D Getley commented that MAJE's new investment manager, Marylebone Partners, "believes that this is an excellent juncture at which to be deploying capital." He also noted that "the board expects the period ahead to be defined by structurally higher rates, variable liquidity, more geopolitical and cyclical volatility, and greater fundamental price dispersion within markets", adding "this is precisely the sort of environment in which a highly selective, fundamental approach that features distinctive bottom-up investments should thrive."

Kepler View

Majedie Investments (MAJE) aims to provide investors with a liquid endowment-like investment strategy. With the appointment of the new investment manager, Marylebone Partners, in January 2023, we believe MAJE now offers investors a truly differentiated investment proposition. The managers' ambition over the long term is to provide shareholders with an alternative to generic investment strategies whose historic success depended on cheap leverage, abundant liquidity, and rising asset prices. Although the strategy is focused on equities, the managers have an unrestricted multi-asset approach which could provide some stability and reduce volatility over time. Although it is too early to analyse performance, we think the portfolio includes some diversifying allocations which we don't think many investors will have exposure to, in addition to the prospect of new, alternative investment ideas.

In our view, the narrowing of the discount since Marylebone took over the management of the trust, reflects the interest in such a differentiated strategy as investors have become more aware of what MAJE now offers, and we note the incentive for the managers is to maintain a narrow discount given the management fee is tied to the market cap. We believe MAJE's mix of fundamental bottom-up ideas with lower levels of cross-correlation to one another has the potential to offer investors an investment proposition capable of performing across the market cycle and acting as a complementary investment for shareholders' often generic equity portfolios.

CLICK HERE TO READ THE FULL REPORT  Visit Kepler Trust Intelligence for more high quality independent investment trust research.

 

Important information

This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASSWFIEELSELF
Date   Source Headline
25th Apr 20245:05 pmRNSFinal Net Asset Value
25th Apr 20245:03 pmRNSMid-Month Estimated Net Asset Value
10th Apr 20245:47 pmRNSEstimated Net Asset Value
2nd Apr 202411:27 amRNSTotal Voting Rights
25th Mar 20245:17 pmRNSHolding(s) in Company
25th Mar 20245:12 pmRNSFinal Net Asset Value
25th Mar 20245:10 pmRNSMid-Month Estimated Net Asset Value
12th Mar 202410:08 amRNSDirectorate Change
11th Mar 20245:39 pmRNSEstimated Net Asset Value
1st Mar 20242:48 pmRNSTotal Voting Rights
26th Feb 20246:15 pmRNSNet Asset Value(s)
26th Feb 20246:15 pmRNSNet Asset Value(s)
22nd Feb 20245:11 pmRNSHolding(s) in Company
1st Feb 202411:11 amRNSTotal Voting Rights
31st Jan 20247:00 amRNSDividend Declaration
25th Jan 20245:52 pmRNSNet Asset Value(s)
25th Jan 20245:52 pmRNSNet Asset Value(s)
18th Jan 202412:46 pmRNSDirector Declaration
17th Jan 20244:17 pmRNSResult of AGM
10th Jan 202412:58 pmRNSNet Asset Value(s)
4th Jan 20242:30 pmRNSHolding(s) in Company
2nd Jan 20243:50 pmRNSResults analysis from Kepler Trust Intelligence
2nd Jan 202412:59 pmRNSTotal Voting Rights
22nd Dec 202312:42 pmRNSNet Asset Value(s)
22nd Dec 202312:41 pmRNSNet Asset Value(s)
18th Dec 20234:06 pmRNSBlock listing Interim Review
18th Dec 20237:00 amRNSAnnual Financial Report
11th Dec 20235:36 pmRNSNet Asset Value(s)
1st Dec 202311:47 amRNSTotal Voting Rights
27th Nov 20232:44 pmRNSNet Asset Value(s)
24th Nov 20235:19 pmRNSNet Asset Value(s)
17th Nov 20234:56 pmRNSHolding(s) in Company
10th Nov 20233:35 pmRNSNet Asset Value(s)
8th Nov 20237:05 amRNSBoard role change
8th Nov 20237:00 amRNSDividend Declaration
1st Nov 202310:42 amRNSTotal Voting Rights
25th Oct 20236:25 pmRNSNet Asset Value(s)
25th Oct 20236:25 pmRNSNet Asset Value(s)
10th Oct 20235:53 pmRNSNet Asset Value(s)
2nd Oct 202311:32 amRNSTotal Voting Rights
25th Sep 20235:14 pmRNSNet Asset Value(s)
25th Sep 20235:13 pmRNSNet Asset Value(s)
11th Sep 20235:45 pmRNSNet Asset Value(s)
1st Sep 202311:42 amRNSTotal Voting Rights
30th Aug 202312:59 pmRNSHolding(s) in Company
25th Aug 202312:59 pmRNSNet Asset Value(s)
25th Aug 202312:58 pmRNSNet Asset Value(s)
10th Aug 20236:13 pmRNSNet Asset Value(s)
2nd Aug 20237:00 amRNSDividend Declaration
1st Aug 20234:12 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.